Objectives: We investigated the prevalence of hepatitis B virus (HBV) markers and occult HBV infection in a general adult population in Korea. Methods: HBsAg, anti-HBs and anti-HBc were analyzed on 1,091 samples of routine medical check-up examinees by chemiluminescence immunoassay. Nucleic acid amplification test (NAT) was performed on 1,047 HBsAg-negative samples by multiplex real-time polymerase chain reaction (PCR) kit for simultaneous detection of HBV, hepatitis C virus, and human immunodeficiency virus (Cobas Taqscreen MPX) in pools of six and reactive pools were resolved to individual samples, and further discriminated by PCR-based assay for HBV (Cobas Ampliscreen HBV). Results: The prevalences of HBsAg, anti-HBc, and anti-HBs were 4.0, 39.3, and 75.4%, respectively. The prevalence of anti-HBc significantly decreased with decreasing age (p< 0.001). Occult HBV infection was found in 7 (0.7%) of 1,047 HBsAg-negative subjects, and 5 of them were anti-HBc-negative. Sequencing of HBV S gene in 3 cases revealed one wild-type and two mutant strains (W74S, F85Y; T63I, W74S, T131N substitutions). Conclusions: This study helps to understand the current status of hepatitis B infection and the prevalence of occult HBV infection in a general adult population in Korea.

Keywords:
Prevalence, Hepatitis B surface antigen, Anti-HBc, Anti-HBs, Occult hepatitis B virus infection, Hepatitis B virus DNA
This content is only available via PDF.
© 2009 S. Karger AG, Basel
2009
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.